文献速递基础与转化研究新药、器械与细胞基因治疗研发

三特异性CD19-CD20-CD22 duoCAR-T在临床前模型清除抗原异质性B细胞肿瘤

Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.
PubMed 文献 · Sci Transl Med · 2021-01-01

针对CD19或CD22单靶点CAR-T治疗后因抗原丢失或下调复发的问题,研究者构建了同时靶向CD19、CD20和CD22的三特异性duoCAR-T,采用慢病毒载体编码两个CAR开放读框。体外筛选信号域组合后,确定含ICOS、OX40或CD27信号域比CD28或4-1BB更有效,并鉴定出四种最佳结合域与信号组合。在体内异种移植白血病和淋巴瘤模型中,三特异性duoCAR-T可强效排斥肿瘤;在由亲本三阳性、CD19阴性、CD20阴性和CD22阴性变异株混合的淋巴瘤模型中,仅三特异性duoCAR-T能快速有效清除肿瘤,各单靶点CAR-T均未能阻止肿瘤进展。

要点

  • 三特异性duoCAR-T同时靶向CD19、CD20和CD22,可克服单靶点CAR-T的抗原逃逸。
  • 含ICOS、OX40或CD27信号域的duoCAR结构比含CD28或4-1BB的更有效。
  • 在抗原异质性B细胞肿瘤模型中,仅三特异性duoCAR-T有效清除肿瘤。

核心结论

  • 多特异性duoCAR-T是预防B细胞恶性肿瘤患者抗原丢失或靶抗原下调所致复发的有前景策略。

研究设计与样本

  • 用慢病毒载体编码两个CAR开放读框构建靶向CD19、CD20和CD22的三特异性duoCAR-T。
  • duoCAR由串联CD19和CD20结合域的CAR通过P2A自剪切肽连接靶向CD22的第二CAR组成。
  • 评估多种胞内T细胞信号基序组合,并在体内异种移植白血病和淋巴瘤模型中验证。

主要发现

  • 含ICOS、OX40或CD27信号域的duoCAR结构比含CD28或4-1BB信号域的更有效。
  • 鉴定出四种最佳结合域与信号组合,可在体内强效排斥异种移植白血病和淋巴瘤肿瘤。
  • 在由亲本三阳性、CD19阴性、CD20阴性和CD22阴性变异株混合的淋巴瘤模型中,仅三特异性duoCAR-T快速有效排斥肿瘤。
  • 各单靶点CAR-T均未能阻止肿瘤进展。
  • 胞内信号谱分析提示所用胞内结构域的不同信号可能贡献上述差异效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A substantial number of patients with leukemia and lymphoma treated with anti-CD19 or anti-CD22 monoCAR-T cell therapy relapse because of antigen loss or down-regulation. We hypothesized that B cell tumor antigen escape may be overcome by a chimeric antigen receptor (CAR) design that simultaneously targets three B cell leukemia antigens. We engineered trispecific duoCAR-T cells with lentiviral vectors encoding two CAR open reading frames that target CD19, CD20, and CD22. The duoCARs were composed of a CAR with a tandem CD19- and CD20-targeting binder, linked by the P2A self-cleaving peptide to a second CAR targeting CD22. Multiple combinations of intracellular T cell signaling motifs were evaluated. The most potent duoCAR architectures included those with ICOS, OX40, or CD27 signaling domains rather than those from CD28 or 4-1BB. We identified four optimal binder and signaling combinations that potently rejected xenografted leukemia and lymphoma tumors in vivo. Moreover, in mice bearing a mixture of B cell lymphoma lines composed of parental triple-positive cells, CD19-negative, CD20-negative, and CD22-negative variants, only the trispecific duoCAR-T cells rapidly and efficiently rejected the tumors. Each of the monoCAR-T cells failed to prevent tumor progression. Analysis of intracellular signaling profiles demonstrates that the distinct signaling of the intracellular domains used may contribute to these differential effects. Multispecific duoCAR-T cells are a promising strategy to prevent antigen loss-mediated relapse or the down-regulation of target antigen in patients with B cell malignancies.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Schneider D, Xiong Y, Wu D, et al. Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models. Sci Transl Med. 2021. PMID: 33762438. doi:10.1126/scitranslmed.abc6401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。